Stockscreener 앱 받기
8.01
11.25%
0.81
시간 외 거래:
8.07
0.06
+0.75%
Satellos Bioscience Inc 주식(MSLE)의 최신 뉴스
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World
(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily
The Canadian biotech stock will beat the market, analyst says - Cantech Letter
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Satellos Bioscience Inc. - Mena FN
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget
Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks
Interim Duchenne and FSHD data on SAT-3247 from Satellos (NASDAQ: MSLE) - Stock Titan
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
(MSCL) Trading Performance and Risk Management (MSCL:CA) - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association - PharmiWeb.com
Satellos to Showcase New SAT-3247 DMD and FSHD Data at 2026 MDA Conference - TipRanks
Satellos (Nasdaq: MSLE) plans SAT-3247 data at 2026 MDA meeting - Stock Titan
(MSCL) Market Insights and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience to Court Investors as Phase 2 DMD Program Advances - TipRanks
Satellos to Participate in Upcoming Investor Conferences - Investing News Network
Satellos to Host February 24 Virtual KOL Event Showcasing SAT-3247 in Duchenne Muscular Dystrophy - TipRanks
Satellos (NASDAQ: MSLE) sets virtual KOL event on SAT-3247 DMD program - Stock Titan
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy - PharmiWeb.com
Inside Satellos’ experimental DMD pill at live online event - Stock Titan
(MSCL) Equity Trading Insights (MSCL:CA) - Stock Traders Daily
US$57.2M raise and Nasdaq Global Market listing for Satellos Bioscience (NASDAQ: MSLE) - Stock Titan
1st boys dosed in Phase 2 trial of oral DMD treatment SAT-3247 - Muscular Dystrophy News
Satellos to Highlight Duchenne Drug Program at Series of Investor Conferences - TipRanks
(MSCL) Dynamic Trading Report (MSCL:CA) - Stock Traders Daily
United StatesMintz Advises Satellos Bioscience In Its US$57.2 Million Initial US Public Offering - Mondaq
Satellos Bioscience (NASDAQ:MSLE) Upgraded at Zacks Research - Defense World
Total liabilities of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience (MSLE) Stock Chart and Price History 2026 - MarketBeat
Satellos Bioscience (MSLE) Stock Trends and Sentiment 2026 - MarketBeat
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy - Investing News Network
Satellos Bioscience Doses First Patient in Phase 2 Pediatric Duchenne Study of SAT-3247 - TipRanks
Satellos Bioscience Administers First Dose of SAT-3247 in Phase 2 Pediatric Trial for Duchenne Muscular Dystrophy - geneonline.com
Free cash flow per share of Satellos Bioscience Inc. – BOATS:MSLE - TradingView
Satellos Bioscience Completes US$57.2 Million Cross-Border Public Offering and Nasdaq Listing - Global Legal Chronicle
This Canadian biotech stock is undervalued, analyst says - Cantech Letter
Satellos price target raised to $40 from $5 at Oppenheimer - Yahoo Finance
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - 富途牛牛
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - PharmiWeb.com
Satellos Bioscience to Highlight Muscle-Regeneration Platform at Guggenheim Biotech Summit 2026 - TipRanks
1.20%
0.06%
자본화:
|
볼륨(24시간):